Dinitrochlorobenzene contact sensitization in patients with end-stage renal disease.
Sixty-nine patients with end-stage renal disease (ESRD) on maintenance hemodialysis were evaluated by topical application of 2,4 dinitrochlorobenzene (DNCB). The initial sensitization dose consisted of 2,000 micrograms of DNCB; challenge doses consisted of 50 and 100 micrograms. Applications to the contralateral forearm in the absence of a spontaneous flare. Only 71% of the ESRD patients tested could be sensitized to DNCB, compared to 100% of normal controls. There was no correlation between DNCB reactivity and the helper/suppressor ratio of circulating lymphocytes in such patients. This study further documents uremic suppression of T-cell responsiveness as manifested by impaired DNCB contact sensitization.
D000328:Adult; D004137:Dinitrochlorobenzene; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007153:Immunologic Deficiency Syndromes / Q000175:diagnosis* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000276:immunology* / Q000628:therapy; D008297:Male; D009578:Nitrobenzenes; D006435:Renal Dialysis; D012882:Skin Tests; D013601:T-Lymphocytes / Q000276:immunology
D004137:Dinitrochlorobenzene; D009578:Nitrobenzenes